WG
INDV icon

Winton Group’s Indivior Pharmaceuticals INDV Stock Holding History

Winton Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$909K Sell
22,143
-182,633
-89% -$6.63M 0.03% 536
2026
Q1 		$6.24M Buy
204,776
+196,676
+2,428% +$6.5M 0.22% 126
2025
Q4 		$291K Buy
+8,100
New +$247K 0.01% 749

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's INDV Position: Q2 2026 in Review

Winton Group reduced its Indivior Pharmaceuticals (INDV) stake by 89% in Q2 2026, selling an estimated $6.63M and leaving 22,143 shares worth $909K. The position accounts for 0.03% of the portfolio, ranked #536.

Winton Group first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.24M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Winton Group held 22,143 shares of Indivior Pharmaceuticals worth $909K as of Q2 2026.
  • Winton Group sold 182,633 Indivior Pharmaceuticals shares in Q2 2026, an estimated $6.63M.
  • Indivior Pharmaceuticals made up 0.03% of Winton Group's portfolio in Q2 2026, its #536 holding.
  • Winton Group first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Winton Group's Indivior Pharmaceuticals position peaked at $6.24M in Q1 2026.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.